Related references
Note: Only part of the references are listed.RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis
Karolin Heinze et al.
CANCERS (2021)
The rediscovery of platinum-based cancer therapy
Sven Rottenberg et al.
NATURE REVIEWS CANCER (2021)
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis
Zhengmao Zhang et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis
Yujing Qin et al.
CANCER BIOMARKERS (2019)
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Ying Z. Mazzu et al.
CLINICAL CANCER RESEARCH (2019)
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Julian Puppe et al.
CLINICAL CANCER RESEARCH (2019)
Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma
Haifeng Zhao et al.
BIOSCIENCE REPORTS (2019)
Association of excision repair cross-complimentary group 1 gene polymorphisms with breast and ovarian cancer susceptibility
Fan Yang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer
Hui Zhang et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants
Sehee Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes
I-Ying Kuo et al.
JOURNAL OF BIOMEDICAL SCIENCE (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer
Masumi Ishibashi et al.
SCIENTIFIC REPORTS (2018)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander et al.
BRITISH JOURNAL OF CANCER (2018)
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
Fang Fang et al.
CANCER RESEARCH (2018)
INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer
J-L Hu et al.
GENE THERAPY (2017)
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
Ning Tang et al.
BMC WOMENS HEALTH (2017)
The association between interleukin-4-590C/T genetic polymorphism, IL-4 serum level, and advanced endometriosis
Andrei M. Malutan et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect
Clifford W. Fong
FREE RADICAL BIOLOGY AND MEDICINE (2016)
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
Yue-shen Wang et al.
ONCOLOGY RESEARCH (2016)
Functionalization of Platinum Complexes for Biomedical Applications
Xiaoyong Wang et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells
Vojtech Novohradsky et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
B. Colmegna et al.
BRITISH JOURNAL OF CANCER (2015)
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Brigid K. Killelea et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinumbased chemotherapy: multi-institutional retrospective analysis
Pei-Jian Peng et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Meta-analysis of Excision Repair Cross-complementation Group 1 (ERCC1) Association with Response to Platinum-based Chemotherapy in Ovarian Cancer
Feng-Ying Li et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Targeting and delivery of platinum-based anticancer drugs
Xiaoyong Wang et al.
CHEMICAL SOCIETY REVIEWS (2013)
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer
K. M. Moxley et al.
GYNECOLOGIC ONCOLOGY (2013)
Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy
Li Yan et al.
PHARMACOGENOMICS (2012)
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins
Andrey Khrunin et al.
PHARMACOGENOMICS (2012)
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
Hans Boesmueller et al.
VIRCHOWS ARCHIV (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
BRCA1 and implications for response to chemotherapy in ovarian cancer
Jennifer E. Quinn et al.
GYNECOLOGIC ONCOLOGY (2009)
Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
K. D. Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Cancer - Crossing over to drug resistance
David M. Livingston et al.
NATURE (2008)
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy
Stephanie Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer
Sokbom Kang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks
LJ Niedernhofer et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Share Paper
